Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.
Int J Mol Sci. 2022 Jun 30;23(13):7325. doi: 10.3390/ijms23137325.
Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors.
树突状细胞介导先天和适应性免疫反应，并直接参与细胞毒性 T 淋巴细胞的激活，后者可以杀死肿瘤细胞。基于树突状细胞的癌症免疫疗法具有临床获益。树突状细胞亚群具有多样性，而肿瘤可以是热肿瘤或冷肿瘤，这取决于其免疫原性；这种异质性会影响基于树突状细胞的免疫疗法的成功。在此，我们综述了树突状细胞及其亚群的发生发展。我们还综述了热肿瘤和冷肿瘤的特征，并简要介绍了与热肿瘤和冷肿瘤相关的治疗试验。最后，我们讨论了热肿瘤和冷肿瘤中的基于树突状细胞的癌症免疫疗法。
